Bacteriophages

What Are Bacteriophages?

Bacteriophages, commonly shortened to phages, are viruses that infect and replicate inside bacterial cells. They were identified independently by Frederick Twort in 1915 and Félix d'Hérelle in 1917, and they are the most abundant biological entities on the planet, with population estimates on the order of 10^31 particles in the biosphere. A phage has no metabolism of its own. It carries a genome of DNA or RNA inside a protein capsid, binds to a specific receptor on the bacterial surface, delivers that genome into the cell, and redirects the host's transcription and translation machinery to build progeny particles.

Phage biology sits at the boundary between microbiology and engineering because the particles are both extremely specific and easy to propagate. A given phage usually infects a narrow range of strains within a single bacterial species, which makes it useful as a targeting element in a sensor or a therapeutic, and a laboratory can grow high-titer stocks cheaply in a bacterial culture.

Structure and Host Recognition

The classical tailed phage morphology consists of an icosahedral or prolate head containing a tightly packed double-stranded DNA genome, a connector or neck, and a contractile or non-contractile tail terminating in a baseplate with tail fibers. The structural and life cycle description in the StatPearls reference on bacteriophages sets out how the tail fibers recognize surface receptors, typically lipopolysaccharide, teichoic acid, outer membrane proteins, pili, or flagella, and how the sheath then acts as a hollow tube for genome injection. Non-tailed families exist as well, including filamentous phages such as M13 and small icosahedral RNA phages. Receptor specificity is what gives phages their narrow host range, and it is also why bacteria can acquire resistance simply by altering or losing a surface structure.

Lytic and Lysogenic Cycles

Phage replication follows one of two broad strategies. In the lytic cycle the incoming genome shuts down host biosynthesis, directs replication of phage DNA and capsid proteins, and ends with assembly and lysis of the cell, releasing tens to hundreds of progeny within roughly twenty to sixty minutes for a typical coliphage. In the lysogenic cycle the genome instead integrates into the host chromosome, or persists as a plasmid, and replicates passively as a prophage each time the bacterium divides until an induction signal such as DNA damage switches it into lytic growth. Temperate phages carrying toxin genes can convert a harmless strain into a pathogenic one, which is one reason therapeutic development favors strictly lytic isolates. Modeling work on the persistence of lytic phages during infection examines how these population dynamics behave inside a host rather than in a well-mixed culture.

Phage Therapy and Engineered Phages

Using phages to treat bacterial infection was pursued in the 1920s and 1930s, then largely displaced by antibiotics in Western medicine while continuing in Georgia and Poland. Rising antibiotic resistance revived the field, and a centenary review of phage therapy in bacterial infection treatment traces the clinical record alongside the regulatory obstacles that a self-replicating, strain-specific therapeutic presents. Practical programs assemble cocktails to broaden coverage and slow resistance, and genetic engineering now allows host range to be retargeted, lysins to be expressed directly, and CRISPR payloads to be delivered that kill only cells carrying a chosen resistance gene.

Applications

Bacteriophages are applied across medicine, industry, and the life sciences, including:

  • Treatment of multidrug-resistant infections under compassionate use and clinical trial protocols
  • Phage-based biosensors and rapid detection of specific bacterial contaminants
  • Biocontrol of pathogens in food processing and agriculture
  • Phage display for antibody and peptide discovery
  • Molecular biology reagents, including T4 and T7 polymerases and lambda cloning vectors
  • Bacterial strain typing and epidemiological source tracing
Loading…